サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1433625

喘息治療薬の市場規模、シェア、動向分析レポート：薬剤クラス別、製品別、投与経路別、地域別、セグメント別予測、2024年～2030年

Asthma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Anti- inflammatory, Bronchodilators), By Product (Inhalers, Nebulizers), By Routeof Administration (Oral, Inhaled), By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
喘息治療薬の市場規模、シェア、動向分析レポート：薬剤クラス別、製品別、投与経路別、地域別、セグメント別予測、2024年～2030年
出版日: 2024年01月25日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

喘息治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の喘息治療薬市場規模は2030年までに379億1,000万米ドルに達し、2024年から2030年までのCAGRは5.3％で拡大すると予測されています。

喘息の有病率の増加と、重症の喘息を治療するための長期的な治療オプションとしての生物製剤の採用が相まって、この市場に有利な成長機会を提供すると期待されています。World Allergy Journalが発表した統計によると、2014年5月、喘息に苦しむ患者は約3億人に上り、不健康な食生活や座りがちなライフスタイルに傾倒する人が多いことから、その数は急増すると予想されています。

また、予測期間中にシングレア、アドエアなどの主要なブランド薬の特許が失効したことで、ジェネリック医薬品の競合が激化し、今後数年間は喘息治療薬市場の成長にマイナスの影響を与えるでしょう。それとは逆に、生物製剤の導入は、喘息治療薬セグメントの市場シェア拡大につながっており、予測期間中も続くと予想されます。

重症喘息の治療において、従来の薬物処方パターンとは対照的に、個別化医療アプローチへの需要が高まっていることは、将来の喘息治療薬市場の出現を後押しすると予想されます。さらに、センサー技術や内蔵無線通信システムを備えた加圧式定量吸入器やスマート吸入器などの技術的に高度な製品の開発は、今後7年間の喘息治療薬市場の成長をさらに促進すると予想されます。

喘息治療薬市場のレポートハイライト

  • 抗炎症薬クラスは、重度の喘息状態をターゲットとする手頃な価格の革新的生物製剤の導入により、予測期間中に急成長を示すと予想されます。その他の特典として、生物学的製剤やモノクローナル抗体によってもたらされる利益に対する認識が高まっており、今後数年間で市場の拡大が見込まれます。
  • ドライパウダー吸入器（DPI）は、他の吸入器よりも臨床効率が高いため、これらのデバイスの採用が増加しているため、最も急成長しているセグメントになると予想されます。ドライパウダー吸入器（DPI）は、他の吸入器よりも臨床効率が高いため、採用が増加しています。このような利点が採用率を急上昇させ、市場浸透率の上昇に寄与しています。
  • 喘息治療薬として吸入合剤のような代替治療法を選択する個人数の増加は、この市場に将来の成長機会をもたらすと予想されています。
  • 喘息治療薬市場で事業を展開する主要企業には、AstraZeneca Plc、Philips Healthcare、Teva Pharmaceutical Industries Ltd.、GlaxoSmithKline Plc、Sanofi-Aventis SA、CareFusion Corporation、Sunovion Pharmaceuticals, Inc.、Boehringer Ingelheim GmbH、Roche Diagnostics、Merck&Co, Inc.などがあります。
  • 市場競争上の優位性を獲得するため、市場リーダーは技術的に高度な機器や新規の改良型生物製剤の導入に注力しています。喘息治療薬の分野では、開発段階にある新規分子が100近くあり、メーカー各社は個別化治療の開発に注力しているため、パイプラインが非常に充実しています。前述した要因は総体的に、近い将来における業界の成長を強化します。
  • 例えば、Teva Pharmaceutical Industries Ltd.のCinquil、RocheのLebrikizumab（フェーズIII）、AB ScienceのMastinib（フェーズII/III）、GlaxoSmithKline PlcのBosatria（フェーズIII）などの医薬品分子は、臨床研究試験中の開発段階にあります。予測期間中に商業利用が可能になれば、この垂直統合型抗がん剤に弾みがつくと期待されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 喘息治療薬市場：変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 喘息治療薬市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 喘息治療薬市場：薬剤クラスの推定・動向分析

  • 薬剤クラスの市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 薬剤クラス別の世界の喘息治療薬市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第5章 喘息治療薬市場：製品の推定・動向分析

  • 製品の市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 製品別の世界の喘息治療薬市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第6章 喘息治療薬市場：投与経路の推定・動向分析

  • 投与経路の市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 投与経路別の世界の喘息治療薬市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第7章 喘息治療薬市場：地域の推定・動向分析

  • 地域の市場シェア分析、2023年と2030年
  • 地域の市場ダッシュボード
  • 世界の地域の市場スナップショット
  • 市場規模と予測動向分析、2018年から2030年まで
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 主要市場参入企業別の最近の動向と影響分析
  • 会社/競合の分類
  • ベンダー情勢
    • Teva Pharmaceutical Industries Ltd
    • GSK plc
    • Merck &Co., Inc.
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca
    • Boehringer Ingelheim International GmbH
    • Sanofi
    • Koninklijke Philips NV
    • BD
    • Covis Pharma
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America asthma therapeutics market, by region, 2018 - 2030 (USD Billion)
  • Table 3 North America asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 4 North America asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 5 North America asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 6 U.S. asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 7 U.S. asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 8 U.S. asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 9 Canada asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 10 Canada asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 11 Canada asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 12 Europe asthma therapeutics market, by region, 2018 - 2030 (USD Billion)
  • Table 13 Europe asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 14 Europe asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 15 Europe asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 16 Germany asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 17 Germany asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 18 Germany asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 19 UK asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 20 UK asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 21 UK asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 22 France asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 23 France asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 24 France asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 25 Italy asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 26 Italy asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 27 Italy asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 28 Spain asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 29 Spain asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 30 Spain asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 31 Denmark asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 32 Denmark asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 33 Denmark asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 34 Sweden asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 35 Sweden asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 36 Sweden asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 37 Norway asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 38 Norway asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 39 Norway asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 40 Asia Pacific asthma therapeutics market, by region, 2018 - 2030 (USD Billion)
  • Table 41 Asia Pacific asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 42 Asia Pacific asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 43 Asia Pacific asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 44 China asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 45 China asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 46 China asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 47 Japan asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 48 Japan asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 49 Japan asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 50 India asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 51 India asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 52 India asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 53 South Korea asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 54 South Korea asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 55 South Korea asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 56 Australia asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 57 Australia asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 58 Australia asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 59 Thailand asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 60 Thailand asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 61 Thailand asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 62 Latin America asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 63 Latin America asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 64 Latin America asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 65 Brazil asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 66 Brazil asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 67 Brazil asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 68 Mexico asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 69 Mexico asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 70 Mexico asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 71 Argentina asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 72 Argentina asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 73 Argentina asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 74 MEA asthma therapeutics market, by region, 2018 - 2030 (USD Billion)
  • Table 75 MEA asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 76 MEA asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 77 MEA asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 78 South Africa asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 79 South Africa asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 80 South Africa asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 81 Saudi Arabia asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 82 Saudi Arabia asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 83 Saudi Arabia asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 84 UAE asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 85 UAE asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 86 UAE asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 87 Kuwait asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 88 Kuwait asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 89 Kuwait asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary Interviews in North America
  • Fig. 5 Primary Interviews in Europe
  • Fig. 6 Primary Interviews in APAC
  • Fig. 7 Primary Interviews in Latin America
  • Fig. 8 Primary Interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Asthma therapeutics market: market outlook
  • Fig. 14 Asthma therapeutics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Asthma therapeutics market driver impact
  • Fig. 20 Asthma therapeutics market restraint impact
  • Fig. 21 Asthma therapeutics market strategic initiatives analysis
  • Fig. 22 Asthma therapeutics market: Drug class movement analysis
  • Fig. 23 Asthma therapeutics market: Drug class outlook and key takeaways
  • Fig. 24 Anti-inflammatory market estimates and forecast, 2018 - 2030
  • Fig. 25 Bronchodilators inhalers market estimates and forecast, 2018 - 2030
  • Fig. 26 Combination therapy inhalers market estimates and forecast, 2018 - 2030
  • Fig. 27 Asthma therapeutics market: Product movement analysis
  • Fig. 28 Asthma therapeutics market: Product outlook and key takeaways
  • Fig. 29 Inhalers market estimates and forecast, 2018 - 2030
  • Fig. 30 Dry powder inhalers market estimates and forecast, 2018 - 2030
  • Fig. 31 Metered dose inhalers market estimates and forecast, 2018 - 2030
  • Fig. 32 Soft mist inhalers market estimates and forecast, 2018 - 2030
  • Fig. 33 Nebulizers market estimates and forecast, 2018 - 2030
  • Fig. 34 Asthma therapeutics market: Route of administration movement analysis
  • Fig. 35 Asthma therapeutics market: Route of administration outlook and key takeaways
  • Fig. 36 Oral market estimates and forecasts, 2018 - 2030
  • Fig. 37 Inhaled market estimates and forecasts,2018 - 2030
  • Fig. 38 Others market estimates and forecasts, 2018 - 2030
  • Fig. 39 Global asthma therapeutics market: Regional movement analysis
  • Fig. 40 Global asthma therapeutics market: Regional outlook and key takeaways
  • Fig. 41 Global asthma therapeutics market shares and leading players
  • Fig. 42 North America market share and leading players
  • Fig. 43 Europe market share and leading players
  • Fig. 44 Asia Pacific market share and leading players
  • Fig. 45 Latin America market share and leading players
  • Fig. 46 Middle East & Africa market share and leading players
  • Fig. 47 North America: SWOT
  • Fig. 48 Europe SWOT
  • Fig. 49 Asia Pacific SWOT
  • Fig. 50 Latin America SWOT
  • Fig. 51 MEA SWOT
  • Fig. 52 North America, by country
  • Fig. 53 North America
  • Fig. 54 North America market estimates and forecasts, 2018 - 2030
  • Fig. 55 U.S. key country dynamics
  • Fig. 56 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 57 Canada key country dynamics
  • Fig. 58 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 59 Europe
  • Fig. 60 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 61 UK key country dynamics
  • Fig. 62 UK market estimates and forecasts, 2018 - 2030
  • Fig. 63 Germany key country dynamics
  • Fig. 64 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 65 France key country dynamics
  • Fig. 66 France market estimates and forecasts, 2018 - 2030
  • Fig. 67 Italy key country dynamics
  • Fig. 68 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 69 Spain key country dynamics
  • Fig. 70 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 71 Denmark key country dynamics
  • Fig. 72 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 73 Sweden key country dynamics
  • Fig. 74 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 75 Norway key country dynamics
  • Fig. 76 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 77 Asia Pacific
  • Fig. 78 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 79 China key country dynamics
  • Fig. 80 China market estimates and forecasts, 2018 - 2030
  • Fig. 81 Japan key country dynamics
  • Fig. 82 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 83 India key country dynamics
  • Fig. 84 India market estimates and forecasts, 2018 - 2030
  • Fig. 85 Thailand key country dynamics
  • Fig. 86 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 87 South Korea key country dynamics
  • Fig. 88 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 89 Australia key country dynamics
  • Fig. 90 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 91 Latin America
  • Fig. 92 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 93 Brazil key country dynamics
  • Fig. 94 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 95 Mexico key country dynamics
  • Fig. 96 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 97 Argentina key country dynamics
  • Fig. 98 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 99 Middle East and Africa
  • Fig. 100 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 101 South Africa key country dynamics
  • Fig. 102 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 103 Saudi Arabia key country dynamics
  • Fig. 104 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 105 UAE key country dynamics
  • Fig. 106 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 107 Kuwait key country dynamics
  • Fig. 108 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 109 Market share of key market players - Asthma therapeutics market
目次
Product Code: 978-1-68038-936-4

Asthma Therapeutics Market Growth & Trends:

The global asthma therapeutics market size is expected to reach USD 37.91 billion by 2030, expanding at a CAGR of 5.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of asthma coupled with the adoption of biologics as a long-term treatment option to treat the severe form of asthma is expected to offer this market with lucrative growth opportunities. According to the statistics published by the World Allergy Journal, in May 2014, patients suffering from asthma registered around 300 million and the number is expected to soar due to a large number of individuals inclining towards unhealthy dietary habits and sedentary lifestyles.

In addition, patent expiration of branded drugs, such as Singulair, Advair and other major drugs during the forecast period has led to a stiff generic competition, which will negatively impact the asthma therapeutics market growth in the coming years. On the contrary, the introduction of biologics is accruing towards the increasing market share of the asthma therapeutics segment, and is anticipated to continue during the forecast period.

The enhanced demand for personalized medicine approach as opposed to the conventional medication prescription pattern for treatment of severe asthma is anticipated to aid the emergence of asthma therapeutics market in the future. In addition, development of technologically advanced products, such as pressurized metered dose inhalers and smart inhalers, equipped with sensor technology and inbuilt wireless communication system is further expected to propel the asthma therapeutics market growth in the next seven years.

Asthma Therapeutics Market Report Highlights:

  • The anti-inflammatory drug class is expected to exhibit rapid growth of over the forecast period owing to the introduction of affordable and innovative biologics targeting the severe asthma condition. In addition, the awareness gained pertaining to the benefits rendered by the biologics and monoclonal antibodies is anticipated to exhibit an upward shift in the market expansion in the coming years.
  • The dry powder inhalers (DPIs) are expected to be the fastest growing segment due to the increasing adoption of these devices because of their high clinical efficiency than other inhalers. They are able to deliver both, small and large-sized drug components and dispense specialty engineered molecules. These related merits have spiked the adoption rates thereby contributing towards the risen market penetration.
  • Rising number of individuals opting for alternative treatment options, such as inhaled fixed-dose combination drugs for asthma medication is anticipated to serve this market with future growth opportunities.
  • Some of the key players operating in the asthma therapeutics market include AstraZeneca Plc, Philips Healthcare, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc, Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Roche Diagnostics, and Merck& Co., Inc.
  • Market leaders are focusing on the introduction of technologically advanced devices and novel, improved biologics to gain a competitive advantage. The asthma therapeutics segment has a very strong pipeline as there are almost 100 novel molecules that are in the development phase and manufacturers are focusing on the development of personalized medication. The aforementioned factors collectively strengthen the industry growth in the near future.
  • For instance, drug molecules, such as Cinquil by Teva Pharmaceutical Industries Ltd., Lebrikizumab by Roche (Phase III), Mastinib by AB Science (Phase II/III), and Bosatria by GlaxoSmithKline Plc (Phase III), are in the development stage undergoing clinical research trials. Their commercial availability during the forecast period is expected to provide a boost to this vertical.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Product
    • 1.2.3. Route of Administration
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for Primary Interviews in North America
      • 1.4.5.2. Data for Primary Interviews in Europe
      • 1.4.5.3. Data for Primary Interviews in Asia Pacific
      • 1.4.5.4. Data for Primary Interviews in Latin America
      • 1.4.5.5. Data for Primary Interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class outlook
    • 2.2.2. Product outlook
    • 2.2.3. Rout of administration outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Asthma Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing incidence of asthma
      • 3.2.1.2. Emergence of novel biologics
      • 3.2.1.3. Rising awareness programs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Patent expiration of branded drugs
      • 3.2.2.2. Regulatory challenges
  • 3.3. Asthma Therapeutics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Asthma Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Drug Class Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Asthma Therapeutics Market by Drug Class Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Anti- inflammatory
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2. Bronchodilators
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.3. Combination Therapy
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Asthma Therapeutics Market: Product Estimates & Trend Analysis

  • 5.1. Product Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Asthma Therapeutics Market by Product Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Inhalers
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 5.4.1.2. Dry Powder
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 5.4.1.3. Metered Dose
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 5.4.1.4. Soft Mist
      • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.2. Nebulizers
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Asthma Therapeutics Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Route of Administration Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Asthma Therapeutics Market by Route of Administration Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Oral
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.2. Inhaled
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.3. Others
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Asthma Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.6. Europe
    • 7.6.1. Germany
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.2. UK
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.4. South Korea
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.5. Australia
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Teva Pharmaceutical Industries Ltd
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. GSK plc
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Merck & Co., Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. F. Hoffmann-La Roche Ltd
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. AstraZeneca
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Boehringer Ingelheim International GmbH
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Sanofi
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Koninklijke Philips N.V.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. BD
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Covis Pharma
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives